Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York. more
Time Frame | ZNTL | Sector | S&P500 |
---|---|---|---|
1-Week Return | -20.31% | -3.72% | -0.05% |
1-Month Return | 1.64% | -1.85% | 2.75% |
3-Month Return | -15.76% | -11.4% | 7.4% |
6-Month Return | -63.05% | -4.41% | 10.47% |
1-Year Return | -77.67% | 4.13% | 27.57% |
3-Year Return | -95.95% | 0.3% | 29.56% |
5-Year Return | -86.64% | 36.62% | 89.3% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 111.00K | 160.00K | 544.00K | 1.43M | 1.39M | [{"date":"2019-12-31","value":7.78,"profit":true},{"date":"2020-12-31","value":11.22,"profit":true},{"date":"2021-12-31","value":38.15,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":97.41,"profit":true}] |
Gross Profit | (111.00K) | (160.00K) | (544.00K) | (1.43M) | (1.39M) | [{"date":"2019-12-31","value":-11100000,"profit":false},{"date":"2020-12-31","value":-16000000,"profit":false},{"date":"2021-12-31","value":-54400000,"profit":false},{"date":"2022-12-31","value":-142600000,"profit":false},{"date":"2023-12-31","value":-138900000,"profit":false}] |
Gross Margin | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 46.84M | 118.79M | 216.54M | 227.29M | 252.55M | [{"date":"2019-12-31","value":18.55,"profit":true},{"date":"2020-12-31","value":47.03,"profit":true},{"date":"2021-12-31","value":85.74,"profit":true},{"date":"2022-12-31","value":90,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (46.84M) | (118.79M) | (216.54M) | (227.29M) | (248.99M) | [{"date":"2019-12-31","value":-4684500000,"profit":false},{"date":"2020-12-31","value":-11878700000,"profit":false},{"date":"2021-12-31","value":-21654200000,"profit":false},{"date":"2022-12-31","value":-22728700000,"profit":false},{"date":"2023-12-31","value":-24898800000,"profit":false}] |
Total Non-Operating Income/Expense | 980.00K | - | - | - | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Pre-Tax Income | (46.36M) | (118.10M) | (164.56M) | (221.30M) | (276.89M) | [{"date":"2019-12-31","value":-4636300000,"profit":false},{"date":"2020-12-31","value":-11810400000,"profit":false},{"date":"2021-12-31","value":-16455900000,"profit":false},{"date":"2022-12-31","value":-22130000000,"profit":false},{"date":"2023-12-31","value":-27689200000,"profit":false}] |
Income Taxes | 15.00K | 444.00K | (297.00K) | (469.00K) | (601.00K) | [{"date":"2019-12-31","value":3.38,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-66.89,"profit":false},{"date":"2022-12-31","value":-105.63,"profit":false},{"date":"2023-12-31","value":-135.36,"profit":false}] |
Income After Taxes | (46.38M) | - | - | - | - | [{"date":"2019-12-31","value":-4637800000,"profit":false},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (46.38M) | (118.55M) | (164.26M) | (220.83M) | (286.35M) | [{"date":"2019-12-31","value":-4637800000,"profit":false},{"date":"2020-12-31","value":-11854800000,"profit":false},{"date":"2021-12-31","value":-16426200000,"profit":false},{"date":"2022-12-31","value":-22083100000,"profit":false},{"date":"2023-12-31","value":-28635000000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (46.38M) | (118.55M) | (164.26M) | (220.83M) | (292.19M) | [{"date":"2019-12-31","value":-4637800000,"profit":false},{"date":"2020-12-31","value":-11854800000,"profit":false},{"date":"2021-12-31","value":-16426200000,"profit":false},{"date":"2022-12-31","value":-22083100000,"profit":false},{"date":"2023-12-31","value":-29219100000,"profit":false}] |
EPS (Diluted) | - | (5.58) | (4.94) | (4.53) | (4.64) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-558,"profit":false},{"date":"2021-12-31","value":-494,"profit":false},{"date":"2022-12-31","value":-453,"profit":false},{"date":"2023-12-31","value":-464,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ZNTL | |
---|---|
Cash Ratio | 7.13 |
Current Ratio | 7.29 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ZNTL | |
---|---|
ROA (LTM) | -25.24% |
ROE (LTM) | -42.89% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ZNTL | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.21 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.79 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ZNTL | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 5.43 |
P/B | 0.62 |
Price/FCF | NM |
EV/R | 7.77 |
EV/Ebitda | NM |
Zentalis Pharmaceuticals Llc (ZNTL) share price today is $3.1
Yes, Indians can buy shares of Zentalis Pharmaceuticals Llc (ZNTL) on Vested. To buy Zentalis Pharmaceuticals Llc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ZNTL stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Zentalis Pharmaceuticals Llc (ZNTL) via the Vested app. You can start investing in Zentalis Pharmaceuticals Llc (ZNTL) with a minimum investment of $1.
You can invest in shares of Zentalis Pharmaceuticals Llc (ZNTL) via Vested in three simple steps:
The 52-week high price of Zentalis Pharmaceuticals Llc (ZNTL) is $18.07. The 52-week low price of Zentalis Pharmaceuticals Llc (ZNTL) is $2.66.
The price-to-earnings (P/E) ratio of Zentalis Pharmaceuticals Llc (ZNTL) is
The price-to-book (P/B) ratio of Zentalis Pharmaceuticals Llc (ZNTL) is 0.62
The dividend yield of Zentalis Pharmaceuticals Llc (ZNTL) is 0.00%
The market capitalization of Zentalis Pharmaceuticals Llc (ZNTL) is $220.21M
The stock symbol (or ticker) of Zentalis Pharmaceuticals Llc is ZNTL